



Developmental Toxicology

Alex Morgan*

Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota

Abstract

Developmental toxicology stands as a critical discipline within the field of toxicology, dedicated to exploring the
mechanisms of toxicity, the critical periods of development, and the potential for adverse effects on the developing
organism. This review discusses the importance of developmental toxicology in drug development and public health,
highlighting the challenges and opportunities in this field.

References

1. Lammerhofer M, Weckwerth W (2013) *Metabolomics in practice: successful strategies to generate and analyze metabolic data*. Weinheim: Wiley-VCH Verlag.
2. Haycock JW (2011) 3D cell culture: a review of current approaches and techniques. *Methods Mol Biol*. 695: 1-15.
3. Fatehullah A, Tan SH, Barker N (2016) Organoids as an in vitro model of human development and disease. *Nat Cell Biol* 18: 246-254.
4. Jeong ES, Kim G, Shin HJ (2015) Increased serum bile acid concentration following low-dose chronic administration of thioacetamide in rats, as evidenced by metabolomic analysis. *Toxicol Appl Pharmacol* 288: 213-222.
5. Mattes W, Davis K, Fabian E (2014) Detection of hepatotoxicity potential with metabolite profiling (metabolomics) of rat plasma. *Toxicol Lett* 230: 467-478.
6. Weiler S, Merz M, Kullak-Ublick GA (2015) Drug-induced liver injury: the dawn of biomarkers? *F1000Prime Rep* 7: 34.
7. Zaitseva K, Hayashi Y, Kusano M (2016) Application of metabolomics to toxicology of drugs of abuse: a mini review of metabolomics approach to acute and chronic toxicity studies. *Drug Metab Pharmacokinet* 31: 21-26.
8. Forgue P, Halouska S, Werth M (2006) NMR metabolic profiling of *Aspergillus nidulans* to monitor drug and protein activity. *J Proteome Res*. 5: 1916-1923.
9. Lefort N, Brown A, Lloyd V (2014) ¹H NMR metabolomics analysis of the effect of dichloroacetate and allopurinol on breast cancers. *J Pharm Biomed Anal* 93:77-85.
10. Yoshinari K, Yamashita K (2016) Analytical chemistry for ADMET research: recent advances and future directions in LC-MS/MS and omics approaches. *Drug Metab Pharmacokinet* 31:1-2.
11. Miura M, Takahashi N (2016) Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC-UV or LC-MS/MS methods. *Drug Metab Pharmacokinet* 31: 12-20.